anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Implant exposure is the most frequent complication after evisceration or enucleation, and multiple surgical techniques for the management of orbital implant exposure. The goal of our study is to investigate the success rate and risk factors for failure of various surgical procedures.
METHODS: This was a retrospective study performed at the University Hospital of Limoges. We collected data from the files of every patient operated on for implant exposure between January 2005 and December 2020. The main criterion was the percentage of success for each procedure. Secondary objectives were to identify risk factors for failure of Müller's muscle flaps and to determine the incidence of post-enucleation socket syndrome depending on whether the orbital implant was maintained.
RESULTS: Fifty-one patients were included: 26 patients who underwent Müller's muscle flap, 16 dermis-fat graft, 3 conjunctival flap, 2 amniotic membrane graft, 1 temporalis fascia graft, 1 buccal mucosa graft, 1 implant rotation, and 1 implant exchange. The dermis-fat grafts were more successful (87.5%) than the Müller's muscle flaps (52.2%) (P=0.0213). The study highlighted the importance of good vascularization of the implant (OR=32.00, P-value=0.0245) for the success of Müller's muscle flaps, and we found no statistically significant difference between the patients who maintained their implants and those who did not (P=0.3865) with regard to the incidence of post-enucleation socket syndrome.
CONCLUSION: Müller's muscle flap may remain a reasonable option in the management of medium-sized implant exposures of well-vascularized implants confirmed on MRI in patients with no systemic healing disorders. Dermis-fat graft remains the option of choice in other cases, especially in large exposures or complicated orbits.
OBJECTIVE: Evidence regarding the efficacy of a low-protein diet for patients with CKD is inconsistent and recommending a low-protein diet for pediatric patients is controversial. There is also a lack of objective biomarkers of dietary intake. The purpose of this study was to identify plasma metabolites associated with dietary intake of protein and to assess whether protein-related metabolites are associated with CKD progression.
METHODS: Nontargeted metabolomics was conducted in plasma samples from 484 Chronic Kidney Disease in Children (CKiD) participants. Multivariable linear regression estimated the cross-sectional association between 949 known, nondrug metabolites and dietary intake of total protein, animal protein, plant protein, chicken, dairy, nuts and beans, red and processed meat, fish, and eggs, adjusting for demographic, clinical, and dietary covariates. Cox proportional hazards models assessed the prospective association between protein-related metabolites and CKD progression defined as the initiation of kidney replacement therapy or 50% eGFR reduction, adjusting for demographic and clinical covariates.
RESULTS: One hundred and twenty-seven (26%) children experienced CKD progression during 5 years of follow-up. Sixty metabolites were significantly associated with dietary protein intake. Among the 60 metabolites, 10 metabolites were significantly associated with CKD progression (animal protein: n = 1, dairy: n = 7, red and processed meat: n = 2, nuts and beans: n = 1), including one amino acid, one cofactor and vitamin, 4 lipids, 2 nucleotides, one peptide, and one xenobiotic. 1-(1-enyl-palmitoyl)-2-oleoyl-glycerophosphoethanolamine (GPE, P-16:0/18:1) was positively associated with dietary intake of red and processed meat, and a doubling of its abundance was associated with 88% higher risk of CKD progression. 3-ureidopropionate was inversely associated with dietary intake of red and processed meat, and a doubling of its abundance was associated with 48% lower risk of CKD progression.
CONCLUSIONS: Untargeted plasma metabolomic profiling revealed metabolites associated with dietary intake of protein and CKD progression in a pediatric population.
NEW MATERIAL:A peptide expressed by formula I (X is absent or amino acid sequence expressed by formula II). USE:A diuretic and hypotensive agent. PREPARATION:For example, a chicken heart is finely cut and treated with boiling water for 5min to inactivate proteases. One M acetic acid and 20mM hydrochloric acid are then added to homogenize the finely cut heart in a mixer, etc. The resultant homogenate is subsequently centrifuged and acetone is added to the supernatant to form precipitates, which are then removed to concentrate the supernatant. The resultant concentrate is then subjected to silica gel column to provide an eluate, which is treated by ion exchange chromatography, eluted with 2M pyridine-acetic acid, etc., to afford an active fraction containing a basic peptide using relaxant activity of a chick rectal specimen as an index. The resultant fraction is successively subjected to gel filtration and ion exchange reversed phase high-speed liquid chromatography and purified to afford the chicken atrial natriuretic active peptide (gamma-chANP) expressed by formula I.
Participants received up to 4 cycles of placebo via vaginal ring. Each cycle consisted of 21 days of placebo vaginal ring use followed by 7 ring-free days.
The investigational treatment will be islet transplant in the presence of induction with ATG/G-CSF and rapamycin treatment for one month. One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver. ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant. Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion. Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
Specific Aim 1: To use advanced functional neuroimaging methods to better understand the nature of attention disruption in patients who have sustained a TBI. We will use imaging data acquired at 3 Tesla (3T) for quantification of regional changes in brain volume over time. The microstructural integrity of white matter tracts will be assessed with diffusion tensor imaging (DTI). Resting state functional MRI (rs-fMRI) from 3T will provide an understanding of the neural networks associated with the brain's baseline activity which may be correlated to cognitive health. We will also try to better understand attention processing in relation to time by employing magnetoencephalography (MEG). By overlaying MEG information on top of structural T1 and T2-weighted MRI sequences, we can get a better overall picture, in both spatial and temporal resolutions, of the brain cognitive tasks. MEG examination will include standard cognitive tasks that rely on intact attention and executive functioning, but are not directly trained by the attention training modules. This allows for assessment of the improvement in functional attention and the ability of training to generalize across related cognitive tasks. All imaging will be corroborated with neuropsychological and neurocognitive testing to assess whether or not abnormalities seen in the imaging are indicative of functionality.

Specific Aim 2: To measure the extent of improvement of patients' attention post cognitive training, and to better understand the processes and timelines that underlie the recovery of attention dysfunction. Comparing the pre- and post-training neurocognitive test results will measure the difference, if any, in attention capacity. These improvements will be correlated to respective advanced imaging. 3T MRI and MEG information from both before and after the cognitive training will be compared to look for any anatomical, functional, and connectivity changes.

Specific Aim 3: To determine which demographic factors (age, race, etc.) and clinical factors (medical history, severity of injury, etc.) contribute to attention impairment, if any. By collecting detailed clinical intake assessments from patients (and/or parents, if applicable) and medical records, as recommended the NIH Common Data Elements for TBI, we will be able to identify any epidemiological variables that significantly contribute to both 1) sustaining attention deficits post-TBI and 2) the propensity for recovery after successful completion of the cognitive training protocol.
A person convicted of sex offences (PCSO) is confronted with several challenges upon re-entry to the community, often facing difficulties accessing housing and employment, and experiencing stigmatisation, hostility and harassment from community members. Given the importance of community support for successful reintegration, we examined differences in public (N = 117) attitudes toward a PCSO against a child (PCSO-C) with mental illness or intellectual disability compared to a neurotypical PCSO-C in an online survey. At present, differences in attitudes towards these groups has not been explored. Results indicated the PCSO-Cs with intellectual disability or mental illness were seen to pose less risk of sexual reoffending and prompted higher levels of reintegration comfort than the neurotypical PCSO-C. Participants' prior personal exposure to mental illness or intellectual disability was unrelated to attitudes, but those who believed that PCSOs in general have a low capacity for change attributed greater risk of sexual reoffending, greater risk of future harm to children, higher levels of blame and lower reintegration comfort, regardless of MI and ID information. Female participants also perceived greater risk of future harm to adults, and older participants estimated higher risk of sexual reoffending than younger participants. Findings have implications for community acceptance of PCSO-Cs and jury decision-making processes and highlight the importance of public education regarding neurodiverse PCSO-Cs and PCSO capacity for change to encourage knowledge-based judgements.
OBJECTIVE: To assess lower extremity deep vein thrombosis (DVT) risk factors after artificial femoral head replacement for elderly femoral neck fractures. A nomogram model was constructed to predict its risk.
METHODS: In analyzing 144 participants who underwent artificial femoral head replacement for elderly femoral neck fractures, researchers collected clinical data to identify factors associated with lower extremity DVT. The study collected numerous variables ranging from age and sex to history of lower extremity DVT and use of anticoagulant drugs after surgery. The patients were in two groups: those who developed DVT (n = 62) and those who did not (n = 82). Multivariate logistic regression analysis helped to identify factors influencing the occurrence of DVT after artificial femoral head replacement. The software packages used were R 4.1.0 and RMS.
RESULTS: Univariate and multivariate regression analysis identified age, ASA level, D-dimer of lower limb DVT, ALB, and PLT as predictive risk factors of lower extremity DVT after artificial femoral head replacement for elderly femoral neck fractures. Those risk factors were used to construct a clinical predictive nomogram. The calibration curves for hypertension in patients with OSAHS risk revealed excellent accuracy of the predictive nomogram model. The unadjusted concordance index (C-index) for the model was 0.877 [95% confidence interval (CI), 0.805-0.942]. The AUC was 0.8375002. Decision curve analysis showed that the predictive model could be applied clinically when the threshold probability was 20 to 80%.
CONCLUSIONS: The researchers constructed and validated a clinical nomogram to predict the occurrence of lower extremity DVT after artificial femoral head replacement in elderly patients with femoral neck fractures. Age, ASA level, D-dimer, and history of lower limb DVT, ALB, and PLT were demonstrated to be predictive risk factors of lower extremity DVT in this circumstance. This practical prognostic nomogram may help improve clinical decision-making.
The invention relates to a preparation technique for ephedra and bighead atractylodes rhizome decoction in novel formed formulation and a production method thereof. The ephedra and bighead atractylodes rhizome decoction comprises the following raw materials as active ingredients in percentages by weight: 9 parts of ephedra, 6 parts of cassia twig, 3 parts of baked liquorice, 9 parts of almond and 12 parts of bighead atractylodes rhizome. The production process comprises the following steps of extraction with alcohol-water, ultrasonic pulverization and extraction, microwave extraction, concentration by water decocting, spray drying at supersonic speed, high pressure homogenization, nanometer grinding, preparation of nanoparticles and the like. The ephedra and bighead atractylodes rhizome decoction has the advantages of multi-synergism and multi-targeting functions of nano-traditional Chinese medicine and the like. After the ephedra decoction is produced in industrial scales, the production cost can be greatly reduced, the product quality can be improved and the targeting and slow controlled release of the medicament can be stronger. After the medicament is made into a pellicle, the pellicle can be adhered to human skins and used for transdermal absorption treatment.
Carcinogenesis: No studies have been conducted. 

Mutagenesis: Loxapine was not mutagenic in the in vitro bacterial reverse mutation (Ames) test, nor clastogenic in the in vitro human peripheral blood lymphocyte chromosomal aberration assay or in the in vivo mouse bone marrow micronucleus assay. 

The loxapine metabolite, 8-OH-loxapine, was not mutagenic in the in vitro bacterial reverse mutation (Ames), test nor clastogenic in the in vitro human peripheral blood lymphocyte chromosomal aberration assay.

Impairment of Fertility:  Loxapine was administered orally in diet to female rats from 14 days prior to mating through day 20 of gestation at doses of 0.19 and 1.28 mg/kg (~0.2 and 1 times the MRHD of 10 mg/day based on mg/m 2 body surface area, respectively). In female rats, mating was decreased at both doses and no mating occurred at a dose equal to the MRHD based on mg/m 2 body surface area because these animals were in persistent diestrus. Loxapine was administered orally in diet to male rats from 60 days prior to and through mating at doses of 0.197 and 1.69 mg/kg (~0.2 and 1.6 times the MRHD based on mg/m 2 body surface area, respectively). In male rats, no effects on fertility were noted at any dose up to 1.6 times the MRHD based on mg/m 2 body surface area. Loxapine was administered orally in diet to female rabbits for 60 days prior to and through mating at doses of 0.23 and 0.77 mg/kg (~0.4 and 1.5 times the MRHD based on mg/m 2 body surface area, respectively). In female rabbits, no effects on fertility were noted at any dose up to 1.5 times the MRHD based on mg/m 2 body surface area.
OBJECTIVE: Schizophrenia (SCZ) is a globally prevalent, severe chronic mental disorder, with cognitive dysfunction being one of its core symptoms. Notably, overweight is exceedingly common among individuals with SCZ, and overweight can also impact cognitive function. Therefore, the relationship between overweight and cognition in SCZ is a clinical issue that is in need of research attention.
METHODS: This study enrolled 77 patients with SCZ, including 36 overweight and 41 non-overweight patients. The Positive and Negative Syndrome Scale (PANSS) was used to assess symptom severity, while cognitive functions were evaluated using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Electroencephalography (EEG) testing was performed, with power spectral analysis conducted across various frequency bands (δ, θ, α, β, low γ, and high γ).
RESULTS: Compared to non-overweight SCZ patients, those overweight exhibited significantly lower RBANS total and index scores in immediate memory, visuospatial/constructional abilities, and delayed memory. EEG spectral analysis revealed that overweight SCZ patients demonstrated significantly lower oscillation power ratios in the β, low γ, and high γ frequency bands compared to their non-overweight counterparts. Correlation analyses indicated a significant positive relationship between β wave activity and RBANS total scores among overweight SCZ patients, suggesting that reduced β power correlates with more severe cognitive dysfunction.
CONCLUSION: Our findings indicate that overweight SCZ patients experience more severe cognitive impairments in a resting state than those who are not overweight, with significant differences in EEG spectrum observed in the β and γ frequency bands. Additionally, our study establishes a correlation between various EEG spectrum dimensions and cognition. This research highlights the effects of overweight on cognition in individuals with SCZ. Additionally, employing EEG technology to study cognitive function in overweight SCZ patients can offer valuable electrophysiological insights.
Stage 1- Luminate 1.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
The invention provides isolated anti-ovarian, colon, prostate, or lung cancer antigen (Ovr232v3) antibodies that bind to Ovr232v3 on a mammalian cell. The invention also encompasses compositions containing an anti-Ovr232v3 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr232v3 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr232v3 antibodies. The invention encompasses a method of producing the anti-Ovr232v3 antibodies. Other aspects of the invention are a method of killing an Ovr232v3-expressing cancer cell via contacting the cancer cell with an anti-Ovr232v3 antibody and a method of alleviating or treating an Ovr232v3 -expressing cancer in a mammal via administering a therapeutically effective amount of the anti-Ovr232v3 antibody to the mammal.
Rationale: Although patients with obstructive sleep apnea (OSA) have a higher risk for coronavirus disease (COVID-19) hospitalization, the causal relationship has remained unexplored. Objectives: To understand the causal relationship between OSA and COVID-19 by leveraging data from vaccination and electronic health records, genetic risk factors from genome-wide association studies, and Mendelian randomization. Methods: We elucidated genetic risk factors for OSA using FinnGen (total N = 377,277), performing genome-wide association. We used the associated variants as instruments for univariate and multivariate Mendelian randomization (MR) analyses and computed absolute risk reduction against COVID-19 hospitalization with or without vaccination. Results: We identified nine novel loci for OSA and replicated our findings in the Million Veteran Program. Furthermore, MR analysis showed that OSA was a causal risk factor for severe COVID-19 (P = 9.41 × 10-4). Probabilistic modeling showed that the strongest genetic risk factor for OSA at the FTO locus reflected a signal of higher body mass index (BMI), whereas BMI-independent association was seen with the earlier reported SLC9A4 locus and a MECOM locus, which is a transcriptional regulator with 210-fold enrichment in the Finnish population. Similarly, multivariate MR analysis showed that the causality for severe COVID-19 was driven by BMI (multivariate MR P = 5.97 × 10-6, β = 0.47). Finally, vaccination reduced the risk for COVID-19 hospitalization more in the patients with OSA than in the non-OSA controls, with respective absolute risk reductions of 13.3% versus 6.3%. Conclusions: Our analysis identified novel genetic risk factors for OSA and showed that OSA is a causal risk factor for severe COVID-19. The effect is predominantly explained by higher BMI and suggests BMI-dependent effects at the level of individual variants and at the level of comorbid causality.
Patients receive placebo IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive placebo IV on days 0, 1, and 2 after autologous or allogeneic hematopoietic stem cell transplantation.
PURPOSE:To obtain a composition improved in stability of FGF protein by blending FGF protein with a water-insoluble hydroxypropyl cellulose. CONSTITUTION:FGF protein is blended with a water insoluble hydroxypropyl cellulose, (preferably containing 5.0-16.0% hydroxypropoxyl radical when the hydroxypropyl cellulose dried at 105 deg.C for 1hr is determined), at a ratio of 0.01-1000000 pts.wt., especially 500-10000 pts.wt. based on 1 pts.wt. FGF protein. The composition may further contain saccharides, proteins, amino acids, sodium chloride and gumi arabic and may be coated with an enteric polymer. The FGF protein includes a protein extracted from an organ of brain, hypophysis, etc., a protein obtained by recombinant DNA technique or FGF mucin.
PURPOSE: A support device for quitting smoking is provided to periodically stimulate a meridian point of ear by placing a compressing clip on the meridian point of ear, thereby correcting imbalance of autonomic nerve system due to nicotine by controlling excitatory and inhibitory state of the cerebral cortex. CONSTITUTION: A support device for quitting smoking includes a compressing clip(100), a power supply unit, a switch unit(500), and a body unit(300). The compressing clip holds the position of a meridian point of ear. The compressing clip has at least one electric needle on an inner side. The electric needle stimulates the meridian point of ear electrically to induce to quit smoking. The power supply unit provides power to the electric needle. The switch unit is installed in a space of the body unit. The switch unit provides or cuts power of the power supply unit by detecting inner air flow by inhalation. An inhalation pipe is connected to one end of the body unit. The power supply unit is located in a space inside the body unit. An inhalation opening(320) to inhale outside air is formed on the other end of the body unit.
PURPOSE: To obtain an infection treating drug contg. bilobalide (deriv.), less liable to cause adverse reaction, excellent in treating effect and useful to treat vaginal, pneumonic or periodontal infection. CONSTITUTION: This infection treating drug contains bilobalide or its pharmaceutically allowable derive. such as ester obtd. by esterifying one or both of the hydroxyl groups of bilobalide with a 2-22C carboxylic acid by an amt. effective in treating infection with a microorganism selected from among Trichomonas vaginalis, staphylococcus aureus, Staphylococcus baecalis, Escherichia coli, Lactobacillus SP and Pneumocystis carnii. This treating drug is preferably administered so that it is kept by 10-100 mg/kg for 5 day in the abdominal cavity.